Experienced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency

Dr. Leona A. Holmberg

Hematology Oncology | Oncology
The Association Of University Physicians
1701 Columbia Rd, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Experienced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
The Association Of University Physicians
1701 Columbia Rd, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leona Holmberg is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Holmberg is rated as an Experienced provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. Her top areas of expertise are Multiple Myeloma, Mantle Cell Lymphoma (MCL), Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Holmberg is currently accepting new patients.

Her clinical research consists of co-authoring 106 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Korean
Mandarin
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1701 Columbia Rd, Seattle, WA 98195
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma
Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug, Other
Study Drugs: Ixazomib Citrate, Lenalidomide
Study Phase: Phase 2
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy
Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy
Enrollment Status: Withdrawn
Publish Date: February 01, 2021
Intervention Type: Procedure, Drug, Other
Study Phase: Phase 2
A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF
A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF
Enrollment Status: Completed
Publish Date: July 12, 2017
Intervention Type: Radiation, Procedure, Drug, Biological
Study Phase: Phase 2
View 4 Less Clinical Trials

106 Total Publications

Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI).
Impact of Post-Autologous Peripheral Blood Stem Cell Transplant (ASCT)- Granulocyte Colony Stimulating Factor (G-CSF) on Toxicity Profiles in Hodgkin Lymphoma (HL) Patients Receiving Pre-ASCT Immune Checkpoint Inhibitors (ICI).
Journal: Transplantation and cellular therapy
Published: October 05, 2025
Similar Doctors
Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Min-chun C. Chen
Hematology Oncology | Hematology | Oncology
Advanced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Min-chun C. Chen
Hematology Oncology | Hematology | Oncology
1003 S 5th St, Ste 3l, 
Tacoma, WA 
 (27.8 miles away)
253-403-1677
Languages Spoken:
English, Castilian, Danish, Hakka, Hindi, Japanese, Mandarin, Portuguese, Punjabi, Russian, Spanish, Taiwanese, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Min-chun Chen is a Hematologist Oncology specialist and a Hematologist in Tacoma, Washington. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML). Dr. Chen is currently accepting new patients.

Kurt A. Norman
Experienced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Kurt A. Norman
Oncology | Hematology Oncology
Experienced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Kurt A. Norman
Oncology | Hematology Oncology

Swedish Cancer Institute Medical Oncology - Ballard

5300 Tallman Avenue Northwest, 0, 
Seattle, WA 
 (3.5 miles away)
206-320-3514
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Norman is board-certified in Internal Medicine, Hematology and Oncology. With twenty years of practice experience, Dr. Norman is well prepared to provide your care. He is person centered-providing the best care based upon national guidelines, but tailored to your specific needs. Dr. Norman is rated as a Distinguished provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Anal Cancer, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Small Cell Lung Cancer (SCLC).

Experienced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Aliakbar R. Dadla
Hematology Oncology | Oncology | Hematology
Experienced in Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
Dr. Aliakbar R. Dadla
Hematology Oncology | Oncology | Hematology

Northwest Medical Specialties PLLC

1624 S I St, Suite 102, 
Tacoma, WA 
 (28.5 miles away)
253-428-8700
Languages Spoken:
English, Arabic, Hindi, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Aliakbar Dadla is a Hematologist Oncology specialist and an Oncologist in Tacoma, Washington. Dr. Dadla is rated as an Advanced provider by MediFind in the treatment of Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency. His top areas of expertise are Hemochromatosis, Thrombocytopenia, Familial Colorectal Cancer, and Agranulocytosis. Dr. Dadla is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Holmberg's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile